SI2299999T1 - Stat3 inhibitorji - Google Patents
Stat3 inhibitorjiInfo
- Publication number
- SI2299999T1 SI2299999T1 SI200931725T SI200931725T SI2299999T1 SI 2299999 T1 SI2299999 T1 SI 2299999T1 SI 200931725 T SI200931725 T SI 200931725T SI 200931725 T SI200931725 T SI 200931725T SI 2299999 T1 SI2299999 T1 SI 2299999T1
- Authority
- SI
- Slovenia
- Prior art keywords
- stat3 inhibitors
- stat3
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/17—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5874208P | 2008-06-04 | 2008-06-04 | |
EP09759351.1A EP2299999B1 (en) | 2008-06-04 | 2009-06-03 | Stat3 inhibitors |
PCT/US2009/046143 WO2009149192A1 (en) | 2008-06-04 | 2009-06-03 | Stat3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2299999T1 true SI2299999T1 (sl) | 2017-12-29 |
Family
ID=41398504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931725T SI2299999T1 (sl) | 2008-06-04 | 2009-06-03 | Stat3 inhibitorji |
Country Status (8)
Country | Link |
---|---|
US (3) | US20110312984A1 (sl) |
EP (1) | EP2299999B1 (sl) |
AU (1) | AU2009256253B2 (sl) |
CA (1) | CA2726987C (sl) |
DK (1) | DK2299999T3 (sl) |
ES (1) | ES2647562T3 (sl) |
SI (1) | SI2299999T1 (sl) |
WO (1) | WO2009149192A1 (sl) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5794922B2 (ja) * | 2009-12-28 | 2015-10-14 | 一般社団法人ファルマバレープロジェクト支援機構 | 1,3,4−オキサジアゾール−2−カルボキサミド化合物 |
JP2013525368A (ja) * | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
CN101836971A (zh) * | 2010-05-21 | 2010-09-22 | 徐学军 | 一种化合物在制备治疗癌症或牛皮癣药物方面的应用 |
FR2962649A1 (fr) * | 2010-07-19 | 2012-01-20 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
WO2012056319A1 (en) * | 2010-10-27 | 2012-05-03 | Dynamix Pharmaceuticals Ltd. | Sulfonamides for the modulation of pkm2 |
EP2675275B1 (en) | 2011-02-14 | 2017-12-20 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of obesity and related disorders |
WO2013012477A1 (en) * | 2011-05-20 | 2013-01-24 | New York University | Propolis and caffeic acid phenethyl ester and uses thereof |
US9486422B2 (en) * | 2011-10-06 | 2016-11-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and the uses of thereof |
US9732038B2 (en) | 2012-06-14 | 2017-08-15 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of STAT3 |
CN104736202B (zh) * | 2012-08-22 | 2021-09-07 | 康奈尔大学 | 用于抑制肌成束蛋白的方法 |
US9365581B2 (en) | 2013-05-02 | 2016-06-14 | The Regents Of The University Of Michigan | Deuterated amlexanox |
EP3021841B1 (en) | 2013-07-18 | 2022-11-16 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
ES2796850T3 (es) * | 2013-07-18 | 2020-11-30 | Baylor College Medicine | Composiciones para la prevención de una reacción alérgica |
US10112933B2 (en) | 2013-07-18 | 2018-10-30 | Baylor College Of Medicine | Methods and compositions for treatment of fibrosis |
US9382204B2 (en) * | 2013-09-27 | 2016-07-05 | Indiana University Research And Technology Corporation | Inhibitors targeting the DNA-binding domain of human STAT3 for treatment of metastatic cancers |
WO2015120436A2 (en) * | 2014-02-10 | 2015-08-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Stat3 phosphorylation during graft-versus-host disease |
EP3107902B1 (en) | 2014-02-20 | 2021-04-07 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | Compounds and methods for inhibiting fascin |
US20160113900A1 (en) * | 2014-10-23 | 2016-04-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Inhibitors of mitochondrial stat3 and uses thereof in modulation of mast cell exocytosis |
EP3407974A4 (en) | 2016-01-29 | 2019-08-28 | The Regents Of The University Of Michigan | ANALOGUES OF AMLEXANOX |
CN105769884B (zh) * | 2016-03-24 | 2018-04-03 | 牡丹江医学院 | 一种治疗肺癌的药物组合物 |
SE540295C2 (en) * | 2016-12-05 | 2018-05-29 | Glactone Pharma Dev Ab | Sulfonamide analogues of galiellalactone |
CN108498503A (zh) * | 2017-02-24 | 2018-09-07 | 河南省锐达医药科技有限公司 | 一类新型细胞信号传导和基因转录激活因子3型(stat3)抑制剂的制备和用途 |
WO2019204427A1 (en) * | 2018-04-19 | 2019-10-24 | Tweardy David J | Methods for measuring and stabilizing stat3 inhibitors |
US11026905B2 (en) | 2018-04-19 | 2021-06-08 | Tvardi Therapeutics, Inc. | STAT3 inhibitors |
EP3773537B1 (en) | 2018-04-19 | 2022-03-23 | Tvardi Therapeutics, Inc. | Stat3 inhibitors |
US20210228548A1 (en) * | 2018-07-25 | 2021-07-29 | Avixgen Inc. | Pharmaceutical composition for preventing, alleviating or treating osteoarthritis, containing rhodanine derivative as active ingredient |
CN110467551B (zh) * | 2019-07-15 | 2022-07-22 | 温州医科大学 | 一种4-甲氧基-n-(1-萘基)苯磺酰胺类stat3小分子抑制剂及其制备和应用 |
EP4093377A1 (en) | 2020-01-24 | 2022-11-30 | Tvardi Therapeutics, Inc. | Therapeutic compounds, formulations, and uses thereof |
WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1447804A (zh) * | 2000-06-20 | 2003-10-08 | 阿特罗吉尼克斯公司 | 1,3-二-(被取代的苯基)-2-丙烯-1-酮及其治疗vcam-1介导的疾病的用途 |
DK1406867T3 (da) | 2001-05-30 | 2009-04-06 | Eisai Corp North America | Thiolalkylbenzoesyrederivater |
EP1664002A1 (en) | 2003-09-17 | 2006-06-07 | Novartis AG | Organic compounds |
US20050287664A1 (en) | 2004-05-27 | 2005-12-29 | Ming-Ji Fann | Cellular proliferation control factors |
US20060148715A1 (en) | 2004-12-20 | 2006-07-06 | Baylor College Of Medicine | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands |
US20070203236A1 (en) * | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
US7960434B2 (en) * | 2006-05-19 | 2011-06-14 | University Of South Florida | Small molecule inhibitors of STAT3 with anti-tumor activity |
KR100786300B1 (ko) | 2006-09-19 | 2007-12-18 | (주)아모레퍼시픽 | 3,4-메틸렌디옥시벤젠 또는 3,4-에틸렌디옥시벤젠 모핵을가지는 4-치환된 벤조산 유도체 화합물을 함유하는항노화용 화장료 조성물 |
-
2009
- 2009-06-03 EP EP09759351.1A patent/EP2299999B1/en active Active
- 2009-06-03 ES ES09759351.1T patent/ES2647562T3/es active Active
- 2009-06-03 CA CA2726987A patent/CA2726987C/en active Active
- 2009-06-03 AU AU2009256253A patent/AU2009256253B2/en active Active
- 2009-06-03 US US12/996,073 patent/US20110312984A1/en not_active Abandoned
- 2009-06-03 SI SI200931725T patent/SI2299999T1/sl unknown
- 2009-06-03 US US12/477,583 patent/US8779001B2/en active Active
- 2009-06-03 WO PCT/US2009/046143 patent/WO2009149192A1/en active Application Filing
- 2009-06-03 DK DK09759351.1T patent/DK2299999T3/en active
-
2014
- 2014-04-15 US US14/253,239 patent/US20140296270A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009149192A1 (en) | 2009-12-10 |
EP2299999B1 (en) | 2017-08-16 |
US20100041685A1 (en) | 2010-02-18 |
DK2299999T3 (en) | 2017-09-25 |
CA2726987C (en) | 2014-02-18 |
US20140296270A1 (en) | 2014-10-02 |
CA2726987A1 (en) | 2009-12-10 |
AU2009256253B2 (en) | 2013-05-16 |
US8779001B2 (en) | 2014-07-15 |
EP2299999A1 (en) | 2011-03-30 |
EP2299999A4 (en) | 2012-01-25 |
ES2647562T3 (es) | 2017-12-22 |
US20110312984A1 (en) | 2011-12-22 |
AU2009256253A1 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2299999A4 (en) | STAT3 INHIBITORS | |
HK1176601A1 (zh) | 抑制劑 | |
ZA201004942B (en) | Ptrrolopyrazine kinase inhibitors | |
HK1179477A1 (en) | Kinase inhibitors | |
IL219447A0 (en) | Kinase inhibitors | |
EP2214669A4 (en) | cytokine inhibitors | |
ZA201100898B (en) | Novel inhibitors | |
IL238583A0 (en) | 2-acylaminopropanol-like as glucosylceramide synthase inhibitors | |
EP2558099A4 (en) | Kinase Inhibitors | |
EP2316491A4 (en) | INHIBITOR OF CELL PROLIFERATION | |
EP2231152A4 (en) | THIENOPYRANONES AS KINASE INHIBITORS | |
HK1137985A1 (en) | Improved raf inhibitors | |
EP2480076A4 (en) | IMIDAZOTHIAZOLIC INHIBITORS OF KINASES | |
ZA201102837B (en) | Phosphodiestarase inhibitors | |
ZA201102179B (en) | Protease inhibitors | |
EP2222662A4 (en) | INHIBITORS OF KYNURENINE AMINO TRANSFERASE | |
GB0916010D0 (en) | JMJD2 demethylase inhibitors | |
EP2346829A4 (en) | INHIBITORS OF STAT3 | |
GB0914726D0 (en) | Kinase inhibitors | |
GB0817425D0 (en) | Protease inhibitors | |
GB0714941D0 (en) | Inhibitors | |
GB0816125D0 (en) | Novel inhibitors | |
GB201019387D0 (en) | Inhibitors | |
GB0707498D0 (en) | Novel inhibitors | |
GB0704589D0 (en) | Novel inhibitors |